Status:
UNKNOWN
Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer
Eligibility:
All Genders
18-69 years
Phase:
PHASE3
Brief Summary
The investigators aimed to compare elective nodal irradiation versus involved field irradiation with or without concurrent chemotherapy and the addition of consolidation chemotherapy for patients with...
Eligibility Criteria
Inclusion
- Age\<70
- Diagnosis of clinical stage T2-4N0-1M1（According to UICC 2002）
- A untreated squamous esophageal carcinoma
- Karnofsky performance status(KPS)≥ 70 and Charlson score ≤3
- Adequate organ function
- No known history of drug allergy
- Blood routine examination : WBC≥4.0
- hepatic and renal function are normal
Exclusion
- Age≥ 70 or ≤ 16
- Already received the treatment of chemotherapy or radiotherapy
- Pregnant or lactating females
- Known drug allergy
- Without agreement of informed consent form
- Insufficient hepatorenal function or Blood routine examination
- Severe cardiovascular diseases, diabetes with uncontrolled blood sugar, mental disorders, uncontrolled severe infection, active ulceration which need intervention.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03328234
Start Date
September 1 2017
End Date
December 31 2022
Last Update
January 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, China, 100021